The regulatory expansion in Australia could drive increased prescription volumes for Optimi's MDMA and psilocybin. Monitor future patient enrollment data and any additional reimbursement agreements. The clean safety profile supports further program scaling.
Price Chart
Executive Summary
Optimi Health acknowledged the TGA's final recommendations expanding Australia's Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens therapist eligibility, allows treatment in non-hospital settings, and extends reimbursement to public and private payers, supporting the commercial market for psychedelic-assisted therapy. No serious adverse events have been reported under the scheme, reinforcing its safety profile.
Key Facts
- TGA updated framework broadens therapist eligibility to include psychotherapists, counsellors, social workers, and Aboriginal and Torres Strait Islander health workers.
- Treatment can now be delivered in any medically supervised environment meeting safety standards, not just hospital settings.
- Reimbursement now spans public (DVA, NDIS, WorkCover) and private (Medibank) payers.
- No serious adverse events reported under the AP scheme since December 2025.
- Optimi supplies GMP-grade MDMA and psilocybin from its Canadian facility to Australian patients under the AP scheme.
Financial Impact
No specific financial figures provided; regulatory expansion may increase addressable patient population and commercial demand for Optimi's products.
Risk Factors
- Forward-looking statements subject to regulatory and market risks; actual adoption may be slower than anticipated.
- Dependence on Australia's AP scheme; changes in policy or reimbursement could impact demand.
- Company has limited revenue and market cap ($18M); execution risk in scaling production and distribution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303582 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.36 | awaiting T+5 | — | $3.26 (−2.84%) |
Oct 20, 2026 6d ago | 6-K | $3.36 | awaiting T+5 | — | $3.26 (−2.84%) |
Oct 7, 2026 19d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.26 (−19.19%) |
Oct 5, 2026 20d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.26 (−20.95%) |
Sep 29, 2026 27d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.26 (−31.70%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.26 (−34.18%) |
Sep 22, 2026 4w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.26 (−34.18%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.26 (−33.38%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.26 (−27.45%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.26 (+33.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers